XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Discontinued Operations (Tables)
 12 Months Ended
Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operations
The following tables summarize the major classes of assets and liabilities related to the discontinued operations of the TransCore, Zetec and CIVCO Radiotherapy businesses, as applicable, as reported in the Consolidated Balance Sheets at December 31:

2021 (1)
2020
Accounts receivable, net$74.7 $117.3 
Inventories, net47.8 33.3 
Unbilled receivables158.2 168.9 
Goodwill405.5 — 
Other intangible assets, net31.0 — 
Other current assets71.4 4.7 
Current assets held for sale788.6 324.2 
Goodwill— 429.2 
Other intangible assets, net— 38.7 
Other assets— 53.7 
Assets held for sale$— $521.6 
Accounts payable$40.3 $50.7 
Accrued compensation27.0 23.5 
Deferred taxes29.5 — 
Other current liabilities62.3 46.6 
Current liabilities held for sale159.1 120.8 
Deferred taxes— 31.0 
Other liabilities— 33.1 
Liabilities held for sale$— $64.1 
(1) All assets and liabilities held for sale were classified as current as it was probable that the sale of TransCore and Zetec would be completed within one year from the balance sheet date.
The following table summarizes the major classes of revenue and expenses constituting net earnings from discontinued operations attributable to the TransCore, Zetec and CIVCO Radiotherapy businesses:

Year ended December 31,
202120202019
Net revenues$638.0 $672.9 $639.1 
Cost of sales372.9400.7352.1
Gross profit265.1272.2287.0
Selling, general and administrative expenses(1)
124.0114.6116.9
Income from operations141.1157.6170.1
Other income (expense), net1.50.3(0.1)
Earnings before income taxes (2)
142.6157.9170.0
Income taxes28.533.742.1
Earnings from discontinued operations, net of tax114.1124.2127.9
Gain on disposition of discontinued operations, net of tax55.9——
Net earnings from discontinued operations$170.0 $124.2 $127.9 
(1) Includes stock-based compensation expense of $5.4, $4.8 and $3.4 for the years ended December 31, 2021, 2020, and 2019, respectively. Stock-based compensation for discontinued operations was previously reported as a component of unallocated corporate general and administrative expenses. In connection with the sale of CIVCO Radiotherapy, we recognized expense of $0.9 associated with accelerated vesting of share-based awards. These charges were recorded as a component of “Gain on disposition of discontinued operations, net of tax” within the Consolidated Statements of Earnings.
(2) Includes depreciation and amortization of $5.2, $7.9 and $7.2 for the years ended December 31, 2021, 2020, and 2019, respectively.